<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363556</url>
  </required_header>
  <id_info>
    <org_study_id>2014-110</org_study_id>
    <nct_id>NCT02363556</nct_id>
  </id_info>
  <brief_title>Comparing Misoprostol Alone to Dilapan With Misoprostol and Comparing Buccal to Vaginal Misoprostol</brief_title>
  <official_title>A Factorial-Design Randomized Controlled Trial Comparing Misoprostol Alone to Dilapan With Misoprostol and Comparing Buccal to Vaginal Misoprostol for Same-Day Cervical Preparation Prior to Dilation &amp; Evacuation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial will use a 2 by 2 factorial design to assess methods of
      cervical preparation prior to Dilation and Evacuations (D&amp;Es) at 14 0/7 to 19 6/7 weeks
      gestational age. In total, 160 woman will be randomized to misoprostol alone or Dilapan with
      misoprostol and separately randomized to buccal or vaginal administration of 400-mcg
      misoprostol. A total of 80 women will receive 400-mcg misoprostol only (40 vaginal and 40
      buccal). Another 80 women will have Dilapan inserted and then use misoprostol (40 vaginal and
      40 buccal). Four to six hours later, the Dilation and Evacuation (D&amp;E) procedure will be
      performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to compare the efficacy of same-day 400-mcg misoprostol
      alone to same-day Dilapan with 400-mcg misoprostol for cervical preparation prior to D&amp;E at
      14 0/7 to 19 6/7 weeks. Patients will first be randomized to misoprostol alone or
      misoprostol-Dilapan, and then separately randomized to use the misoprostol buccally or
      vaginally.

      The primary outcome measure is total procedure time. Secondary outcomes include D&amp;E procedure
      time, initial cervical dilation (measured by the largest Hegar dilator accepted without
      resistance prior to the start of the procedure), patient-oriented outcomes (side effects of
      buccal and vaginal misoprostol), and patient acceptability and satisfaction.

      The investigators have chosen a randomized controlled trial with a factorial design to be
      conducted at Washington Hospital Center and Planned Parenthood of Metropolitan Washington. A
      total up to 180 English speaking women will be enrolled in the study so that 160 will be
      randomized and receive study interventions. The study will enroll healthy women, over the age
      of 18, eligible for non-urgent D&amp;E at 14 0/7 weeks to 19 6/7 weeks, confirmed by sonogram.
      The women will be randomized to receive either misoprostol alone or Dilapan with misoprostol.
      Women will then be randomized to receive 400-mcg of misoprostol either buccally or vaginally.
      Computer generated randomization will be utilized to assign treatment arms. Approximately 4-6
      hours prior to procedure, women will be randomly assigned to one of the following treatment
      combinations:

        1. Misoprostol 400-mcg vaginally

        2. Misoprostol 400-mcg buccally

        3. Dilapan insertion with 400-mcg misoprostol vaginally

        4. Dilapan insertion with 400-mcg misoprostol buccally
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total procedure time</measure>
    <time_frame>4-6hrs</time_frame>
    <description>Total procedure time is defined as the time required for dilator insertion plus the D&amp;E time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>D&amp;E procedure time</measure>
    <time_frame>0-60 mins</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial cervical dilation</measure>
    <time_frame>0-10 mins</time_frame>
    <description>Measured by the largest Hegar dilator accepted without resistance prior to the start of the procedure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Second Trimester Abortions</condition>
  <arm_group>
    <arm_group_label>Misoprostol Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled into this arm of the study will receive misoprostol 400-mcg only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dilapan with Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled into this arm of the study will receive Dilapan with 400-mcg misoprostol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Misoprostol administered vaginally</intervention_name>
    <arm_group_label>Misoprostol Alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Misoprostol administered buccally</intervention_name>
    <arm_group_label>Misoprostol Alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Misoprostol administered vaginally with Dilapan</intervention_name>
    <arm_group_label>Dilapan with Misoprostol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Misoprostol administered buccally with Dilapan</intervention_name>
    <arm_group_label>Dilapan with Misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy pregnant women

          -  18 years of age or older

          -  Eligible for non-urgent Dilation and Evacuations at 14 0/7 - 19 6/7 weeks gestation
             confirmed by sonogram.

        Exclusion Criteria:

          -  Women who do not speak English.

          -  Fetal demise

          -  Intolerance, allergy or contraindication to misoprostol or Dilapan.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Matthew Reeves, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedStar Washington Hospital Center &amp; Planned Parenthood of Metropolitan Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Jamilah Shakir, MD MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Medstar Washington Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood Metropolitan Washington</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medstar Health Research Institute</investigator_affiliation>
    <investigator_full_name>Matthew Reeves</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Cervical Dilation</keyword>
  <keyword>Dilation and Evacuation</keyword>
  <keyword>Misoprostol</keyword>
  <keyword>Misoprostol-Dilapan</keyword>
  <keyword>Abortion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

